A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECT: There is evidence that 5-aminolevulinic acid (ALA) facilitates greater extent of resection and improves 6-month progression-free survival in patients with high-grade gliomas. But there remains a paucity of studies that have examined whether the intensity of ALA fluorescence correlates with tumor cellularity. Therefore, a Phase II clinical trial was undertaken to examine the correlation of intensity of ALA fluorescence with the degree of tumor cellularity. METHODS: A single-center, prospective, single-arm, open-label Phase II clinical trial of ALA fluorescence-guided resection of high-grade gliomas (Grade III and IV) was held over a 43-month period (August 2010 to February 2014). ALA was administered at a dose of 20 mg/kg body weight. Intraoperative biopsies from resection cavities were collected. The biopsies were graded on a 4-point scale (0 to 3) based on ALA fluorescence intensity by the surgeon and independently based on tumor cellularity by a neuropathologist. The primary outcome of interest was the correlation of ALA fluorescence intensity to tumor cellularity. The secondary outcome of interest was ALA adverse events. Sensitivities, specificities, positive predictive values (PPVs), negative predictive values (NPVs), and Spearman correlation coefficients were calculated. RESULTS: A total of 211 biopsies from 59 patients were included. Mean age was 53.3 years and 59.5% were male. The majority of biopsies were glioblastoma (GBM) (79.7%). Slightly more than half (52.5%) of all tumors were recurrent. ALA intensity of 3 correlated with presence of tumor 97.4% (PPV) of the time. However, absence of ALA fluorescence (intensity 0) correlated with the absence of tumor only 37.7% (NPV) of the time. For all tumor types, GBM, Grade III gliomas, and recurrent tumors, ALA intensity 3 correlated strongly with cellularity Grade 3; Spearman correlation coefficients (r) were 0.65, 0.66, 0.65, and 0.62, respectively. The specificity and PPV of ALA intensity 3 correlating with cellularity Grade 3 ranged from 95% to 100% and 86% to 100%, respectively. In biopsies without tumor (cellularity Grade 0), 35.4% still demonstrated ALA fluorescence. Of those biopsies, 90.9% contained abnormal brain tissue, characterized by reactive astrocytes, scattered atypical cells, or inflammation, and 8.1% had normal brain. In nonfluorescent (ALA intensity 0) biopsies, 62.3% had tumor cells present. The ALA-associated complication rate among the study cohort was 3.4%. CONCLUSIONS: The PPV of utilizing the most robust ALA fluorescence intensity (lava-like orange) as a predictor of tumor presence is high. However, the NPV of utilizing the absence of fluorescence as an indicator of no tumor is poor. ALA intensity is a strong predictor for degree of tumor cellularity for the most fluorescent areas but less so for lower ALA intensities. Even in the absence of tumor cells, reactive changes may lead to ALA fluorescence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423
Stummer, W., Novotny, A., Stepp, H., Goetz, C., Bise, K., & Reulen, H. J. (2000) · Journal of Neurosurgery · doi:10.3171/jns.2000.93.6.1003 · Cited by 881
Shinoda, J., Yano, H., Yoshimura, S.-I., Okumura, A., Kaku, Y., Iwama, T., & Sakai, N. (2003) · Journal of Neurosurgery · doi:10.3171/jns.2003.99.3.0597 · Cited by 249
Cited by
Clinical development and potential of photothermal and photodynamic therapies for cancer
Li, X., Lovell, J. F., Yoon, J., & Chen, X. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0410-2 · Cited by 3,456
Maximizing safe resection of low- and high-grade glioma
Hervey-Jumper, S. L., & Berger, M. S. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2110-4 · Cited by 471
Self-citation5-ALA and FDA Approval for Glioma Surgery
Hadjipanayis, C. G., & Stummer, W. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03098-y · Cited by 338
Casas, A. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.008 · Cited by 164
Jaber, M., Ewelt, C., Wölfer, J., Brokinkel, B., Thomas, C., Hasselblatt, M., Grauer, O., & Stummer, W. (2019) · Neurosurgery · doi:10.1093/neuros/nyy365 · Cited by 66
Schupper, A. J., Baron, R. B., Cheung, W., Rodriguez, J., Kalkanis, S. N., Chohan, M. O., Andersen, B. J., Chamoun, R., Nahed, B. V., Zacharia, B. E., et al. (2022) · Journal of Neurosurgery · doi:10.3171/2021.5.jns21310 · Cited by 59
Kaneko, S., Suero Molina, E., Ewelt, C., Warneke, N., & Stummer, W. (2019) · Neurosurgery · doi:10.1093/neuros/nyz129 · Cited by 56
Fluorescence real-time kinetics of protoporphyrin IX after 5-ALA administration in low-grade glioma
Kaneko, S., Suero Molina, E., Sporns, P., Schipmann, S., Black, D., & Stummer, W. (2022) · Journal of Neurosurgery · doi:10.3171/2020.10.jns202881 · Cited by 28
Strickland, B. A., Wedemeyer, M., Ruzevick, J., Micko, A., Shahrestani, S., Daneshmand, S., Shiroishi, M. S., Hwang, D. H., Attenello, F., Chen, T., et al. (2022) · Journal of Neurosurgery · doi:10.3171/2022.1.jns212562 · Cited by 15
Metadata
- Authors
- Lau, D., Hervey-Jumper, S. L., Chang, S., Molinaro, A. M., McDermott, M. W., Phillips, J. J., & Berger, M. S.
- Venue
- Journal of Neurosurgery
- Published
- 2016-05
- Volume
- 124
- Issue
- 5
- Pages
- 1300-1309
- ISSN
- 0022-3085 (ISSN-L)
- 1933-0693
- OpenAlex
- W2135282485
- Cited by
- 171
- References
- 3
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.